BioCentury
ARTICLE | Clinical News

Thyrogen thyrotropin alpha regulatory update

October 29, 2012 7:00 AM UTC

EMA's CHMP recommended changing the label of thyroid cancer treatment Thyrogen thyrotropin alpha from Sanofi's Genzyme Corp. subsidiary to include a radioiodine dose range. Specifically, Thyrogen would be used for pre-therapeutic stimulation in combination with 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer. ...